Enlaza Therapeutics
San Diego, US · Founded 2020 · 68 employees on LinkedIn · 9 known investors
Find your way into Enlaza Therapeutics
231 people in our graph share verified history with the Enlaza Therapeutics team — schools, employers, funds. One of them is your warm intro.
Aasim Hasanunlockedknows Sergio G. Duron · together at The University of Texas at Austin (overlapped)
×4knows the team · via The University of Texas at Austin
×2knows the team · via The Scripps Research Institute
×3knows the team · via Stony Brook University
×2knows the team · via Avalon BioVentures
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
Founders & leadership
Enlaza Therapeutics was founded in 2020 by Sergio Duron and Sanford Madigan.
SD
SM
Sanford MadiganinCo-Founder, President & Chief Business OfficerHe has over 30 years of experience in biotech leadership, including founding and serving as CEO of Nerio Therapeutics (acquired by Boehringer Ingelheim in 2024) and Calporta Therapeutics (acquired by Merck in 2019), as well as roles at Avalon Bioventures. Madigan holds a Ph.D. in genetics and B.S. in biochemistry from SUNY Stony Brook, and completed postdoctoral training at the Salk Institute for Biological Studies.
AH
Analeah HeidtinChief Scientific Officer
Board
MM
Marcos MillaBoard director
JL
Jay LichterBoard director
TR
Tighe ReardonBoard director
JT
James TopperBoard director
SS
Stephen SquintoBoard director
SC
Shelley ChuBoard director
Investors · 9
Frazier Life Sciences✓ verifiedPalo Alto
Lightspeed Venture Partners✓ verifiedMenlo Park · $1.7M – $87M
Samsara BioCapital✓ verifiedPalo Alto
Avalon BioVenturesSan Diego
Pappas CapitalDurham
Pfizer Venture Investments$5M – $20M
J.P. Morgan Asset Managementreported
OrbiMedreportedNew York · $1M – $75Mvia Stephen Squinto · board
Also in the syndicate · 1
Life Sciences Group of J.P. Morgan Private Capitallead
Reported raises · per SEC filings
Form D private placements$134.3M disclosed across 3 of 7 rounds · 2021–2025
▶$15MraisedSep 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$15MraisedSep 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marcos MillaDirector
- Stephen SquintoDirector
- Tighe ReardonExecutive Officer
- Jay LichterDirector
- Shelley ChuDirector
- Sergio DuronExecutive Officer, Director
- James TopperDirector
- Sanford MadiganExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$84MraisedAug 2024 · 16 investors · PharmaceuticalsRule 506(b)
▶$84MraisedAug 2024 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marcos MillaDirector
- Jay LichterDirector
- Sergio DuronExecutive Officer, Director
- Tighe ReardonExecutive Officer
- James TopperDirector
- Stephen SquintoDirector
- Sanford MadiganExecutive Officer
- Shelley ChuDirector
- Offering amount
- $110M
- Amount sold
- $84M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$35.3MraisedNov 2022 · 10 investors · PharmaceuticalsRule 506(b)
▶$35.3MraisedNov 2022 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Sanford MadiganExecutive Officer
- James TopperDirector
- Jay LichterDirector
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- Marcos MillaDirector
- Sergio DuronExecutive Officer, Director
- Offering amount
- $61.3M
- Amount sold
- $35.3M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedOct 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedOct 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James TopperDirector
- Sergio DuronExecutive Officer, Director
- Jay LichterDirector
- Sanford MadiganExecutive Officer
- Marcos MillaDirector
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$312KofferedOct 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$312KofferedOct 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James TopperDirector
- Tighe ReardonExecutive Officer
- Shelley ChuDirector
- Sergio DuronExecutive Officer, Director
- Sanford MadiganExecutive Officer
- Marcos MillaDirector
- Jay LichterDirector
- Offering amount
- $312K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedAug 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedAug 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James TopperDirector
- Sergio DuronExecutive Officer, Director
- Marcos MillaDirector
- Sanford MadiganExecutive Officer
- Jay LichterDirector
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedJun 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shelley ChuDirector
- Tighe ReardonExecutive Officer
- Sanford MadiganExecutive Officer
- Sergio DuronExecutive Officer, Director
- Marcos MillaDirector
- James TopperDirector
- Jay LichterDirector
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Enlaza Therapeutics do?
- Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.
- Who founded Enlaza Therapeutics?
- Enlaza Therapeutics was founded by Sergio Duron, Sanford Madigan in 2020.
- Who are Enlaza Therapeutics's investors?
- Enlaza Therapeutics's investors include Frazier Life Sciences, Lightspeed Venture Partners, Samsara BioCapital, Avalon BioVentures, Pappas Capital, Pfizer Venture Investments, J.P. Morgan Asset Management, OrbiMed.
- How much funding has Enlaza Therapeutics raised?
- Enlaza Therapeutics has disclosed $134.3M raised across 3 of its 7 known rounds.
- Where is Enlaza Therapeutics headquartered?
- Enlaza Therapeutics is headquartered in San Diego, US.